Literature DB >> 33776665

Intraoperative Characterization of Subthalamic Nucleus-to-Cortex Evoked Potentials in Parkinson's Disease Deep Brain Stimulation.

Lila H Levinson1,2, David J Caldwell2,3, Jeneva A Cronin2,3, Brady Houston1,2, Steve I Perlmutter1,2,4, Kurt E Weaver1,2,5, Jeffrey A Herron1,2,6, Jeffrey G Ojemann1,2,6, Andrew L Ko1,2,6.   

Abstract

Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is a clinically effective tool for treating medically refractory Parkinson's disease (PD), but its neural mechanisms remain debated. Previous work has demonstrated that STN DBS results in evoked potentials (EPs) in the primary motor cortex (M1), suggesting that modulation of cortical physiology may be involved in its therapeutic effects. Due to technical challenges presented by high-amplitude DBS artifacts, these EPs are often measured in response to low-frequency stimulation, which is generally ineffective at PD symptom management. This study aims to characterize STN-to-cortex EPs seen during clinically relevant high-frequency STN DBS for PD. Intraoperatively, we applied STN DBS to 6 PD patients while recording electrocorticography (ECoG) from an electrode strip over the ipsilateral central sulcus. Using recently published techniques, we removed large stimulation artifacts to enable quantification of STN-to-cortex EPs. Two cortical EPs were observed - one synchronized with DBS onset and persisting during ongoing stimulation, and one immediately following DBS offset, here termed the "start" and the "end" EPs respectively. The start EP is, to our knowledge, the first long-latency cortical EP reported during ongoing high-frequency DBS. The start and end EPs differ in magnitude (p < 0.05) and latency (p < 0.001), and the end, but not the start, EP magnitude has a significant relationship (p < 0.001, adjusted for random effects of subject) to ongoing high gamma (80-150 Hz) power during the EP. These contrasts may suggest mechanistic or circuit differences in EP production during the two time periods. This represents a potential framework for relating DBS clinical efficacy to the effects of a variety of stimulation parameters on EPs.
Copyright © 2021 Levinson, Caldwell, Cronin, Houston, Perlmutter, Weaver, Herron, Ojemann and Ko.

Entities:  

Keywords:  Parkinson’s disease; deep brain stimulation; electrocorticography; evoked potential; high-frequency stimulation; subthalamic nucleus

Year:  2021        PMID: 33776665      PMCID: PMC7990794          DOI: 10.3389/fnhum.2021.590251

Source DB:  PubMed          Journal:  Front Hum Neurosci        ISSN: 1662-5161            Impact factor:   3.473


  33 in total

1.  Pallidal stimulation for parkinsonism: improved brain activation during sequence learning.

Authors:  Masafumi Fukuda; Maria Felice Ghilardi; Maren Carbon; Vijay Dhawan; Yilong Ma; Andrew Feigin; Marc J Mentis; Claude Ghez; David Eidelberg
Journal:  Ann Neurol       Date:  2002-08       Impact factor: 10.422

2.  Disrupted dopamine transmission and the emergence of exaggerated beta oscillations in subthalamic nucleus and cerebral cortex.

Authors:  Nicolas Mallet; Alek Pogosyan; Andrew Sharott; Jozsef Csicsvari; J Paul Bolam; Peter Brown; Peter J Magill
Journal:  J Neurosci       Date:  2008-04-30       Impact factor: 6.167

3.  Functional connectivity in human cortical motor system: a cortico-cortical evoked potential study.

Authors:  Riki Matsumoto; Dileep R Nair; Eric LaPresto; William Bingaman; Hiroshi Shibasaki; Hans O Lüders
Journal:  Brain       Date:  2006-10-17       Impact factor: 13.501

4.  Neurophysiological effects of stimulation through electrodes in the human subthalamic nucleus.

Authors:  P Ashby; Y J Kim; R Kumar; A E Lang; A M Lozano
Journal:  Brain       Date:  1999-10       Impact factor: 13.501

5.  Projections of the precentral motor cortex and other cortical areas of the frontal lobe to the subthalamic nucleus in the monkey.

Authors:  K H Monakow; K Akert; H Künzle
Journal:  Exp Brain Res       Date:  1978-11-15       Impact factor: 1.972

Review 6.  Deep Brain Stimulation for Movement Disorders of Basal Ganglia Origin: Restoring Function or Functionality?

Authors:  Thomas Wichmann; Mahlon R DeLong
Journal:  Neurotherapeutics       Date:  2016-04       Impact factor: 7.620

7.  Exaggerated phase-amplitude coupling in the primary motor cortex in Parkinson disease.

Authors:  Coralie de Hemptinne; Elena S Ryapolova-Webb; Ellen L Air; Paul A Garcia; Kai J Miller; Jeffrey G Ojemann; Jill L Ostrem; Nicholas B Galifianakis; Philip A Starr
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-07       Impact factor: 11.205

8.  Clustered Desynchronization from High-Frequency Deep Brain Stimulation.

Authors:  Dan Wilson; Jeff Moehlis
Journal:  PLoS Comput Biol       Date:  2015-12-29       Impact factor: 4.475

9.  Distinct cortical responses evoked by electrical stimulation of the thalamic ventral intermediate nucleus and of the subthalamic nucleus.

Authors:  C J Hartmann; J Hirschmann; J Vesper; L Wojtecki; M Butz; A Schnitzler
Journal:  Neuroimage Clin       Date:  2018-11-03       Impact factor: 4.881

10.  ECoG Beta Suppression and Modulation During Finger Extension and Flexion.

Authors:  Julian Unterweger; Martin Seeber; Stavros Zanos; Jeffrey G Ojemann; Reinhold Scherer
Journal:  Front Neurosci       Date:  2020-02-13       Impact factor: 4.677

View more
  3 in total

1.  The cortical evoked potential corresponds with deep brain stimulation efficacy in rats.

Authors:  Isaac R Cassar; Warren M Grill
Journal:  J Neurophysiol       Date:  2022-04-07       Impact factor: 2.974

2.  Subthalamic deep brain stimulation of an anatomically detailed model of the human hyperdirect pathway.

Authors:  Clayton S Bingham; Cameron C McIntyre
Journal:  J Neurophysiol       Date:  2022-03-23       Impact factor: 2.974

Review 3.  Deep Brain Stimulation Treating Dystonia: A Systematic Review of Targets, Body Distributions and Etiology Classifications.

Authors:  Houyou Fan; Zijian Zheng; Zixiao Yin; Jianguo Zhang; Guohui Lu
Journal:  Front Hum Neurosci       Date:  2021-11-26       Impact factor: 3.169

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.